SCHEMBL5367766

SCHEMBL5367766

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(OC)c(OC)c(OC)c1)C(=O)N2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.61
PLK4 O00444 2/20 0.59
NTRK1 P04629 1/20 0.55
FCER2 P06734 1/20 0.55
SYK P43405 1/20 0.55
NTRK3 Q16288 1/20 0.55
NTRK2 Q16620 1/20 0.55
SRC P12931 2/20 0.53
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CDK2 P24941 2/20 0.52
LRRK2 Q5S007 1/20 0.51
PSEN1 P49768 1/20 0.51
PSEN2 P49810 1/20 0.51
APH1B Q8WW43 1/20 0.51
NCSTN Q92542 1/20 0.51
APH1A Q96BI3 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359504 0.89 PSEN1 (0.56) GSK3BPLK4NTRK1FCER2SYK
SCHEMBL5357858 0.89 LRRK2 (0.65) GSK3BPLK4NTRK1FCER2SYK
SCHEMBL5363360 0.87 SYK (0.62) NTRK1FCER2SYKNTRK3NTRK2
SCHEMBL5368923 0.86 ERBB2 (0.59) GSK3BPLK4NTRK1FCER2SYK
SCHEMBL5373774 0.86 SYK (0.53) GSK3BPLK4NTRK1FCER2SYK
SCHEMBL7138911 0.85 NTRK1 (0.54) NTRK1FCER2SYKNTRK3NTRK2
SCHEMBL5367549 0.85 SYK (0.58) GSK3BPLK4NTRK1FCER2SYK
SCHEMBL5361448 0.84 SYK (0.65) NTRK1FCER2SYKNTRK3NTRK2
SCHEMBL5358665 0.84 SYK (0.57) NTRK1FCER2SYKNTRK3NTRK2
SCHEMBL5376631 0.84 SYK (0.58) GSK3BNTRK1FCER2SYKNTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK GSK3B 315/4885PLK4 42/4885NTRK1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.